Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML

The therapeutic approach to Chronic Myeloid Leukemia (CML) has changed since the advent of the tyrosine kinase inhibitor (TKI) imatinib, which was then followed by the second generation TKIs dasatinib, nilotinib, and, finally, by ponatinib, a third-generation drug. At present, these therapeutic opti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Mol Sci
Hlavní autoři: Carofiglio, Francesca, Lopalco, Antonio, Lopedota, Angela, Cutrignelli, Annalisa, Nicolotti, Orazio, Denora, Nunzio, Stefanachi, Angela, Leonetti, Francesco
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2020
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7352889/
https://ncbi.nlm.nih.gov/pubmed/32586039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21124469
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky